SOTIO completes acquisition of Cytune Pharma

30 August 2018

Czech biotech firm SOTIO, part of the privately-owned PPF Group, has completed the acquisition of Cytune Pharma, a firm developing inrterleukin (IL)-15 based therapies for the treatment of cancer, for an undisclosed sume

SOTIO will continue development of lead program SO-C101 (RLI-15) and intends to initiate first-in-human clinical trials in early 2019. All Cytune projects will be developed as part of SOTIO’s pipeline.

Following the completion of the deal, which was announced in 2015, Cytune is to become an important part of SOTIO’s activities in the biotech sector, and will closely collaborate with its affiliate Accord Research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK